| Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. | |
| | |
MedLine Citation:
|
PMID: 8774625 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lipid lowering therapies were employed to prevent restenosis following elective percutaneous transluminal coronary angioplasty (PTCA). The effect of probucol was compared to that of Pravastatin in 141 coronary atherosclerosis patients. Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2). Pravastatin (10 mg/day) was administered for at least 30 days prior to PTCA (38 patients, group V-1) or less than 14 days prior to PTCA (42 patients, group V-2). In group P-1, the patient restenosis rate was 17.6% and lesion restenosis rate was 14%. These rates were significantly lower than those of group V-1, which were 44.7% and 40.4% respectively (p < 0.05). The respective values were 48.1% and 51.8% in group P-2 (p < 0.05, vs group P-1) and 35.7% and 34% (p < 0.05, vs group P-1) in group V-2. Probucol seems to work, not only by lowering cholesterol but also by its antioxidative properties when administered for a sufficient period prior to PTCA. |
| | |
Authors:
|
Y J Lee; H Daida; H Yokoi; H Miyano; J Takaya; H Sakurai; H Mokuno; H Yamaguchi |
Related Documents
:
|
7982415 - Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty:... 21936735 - Six and 12 months' effects of individual joint protection education in people with rheu... 9874045 - Two- to three-year follow-up of patients with single-vessel coronary artery disease ran... 16373265 - Drug-eluting stents for the treatment of in-stent restenosis--'real world' double centr... 20634725 - The intermediate clinical outcome and its limitations of bryan cervical arthroplasty fo... 7995835 - Endothelial cell seeded dacron aortobifurcated grafts: platelet deposition and long-ter... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Japanese heart journal Volume: 37 ISSN: 0021-4868 ISO Abbreviation: Jpn Heart J Publication Date: 1996 May |
Date Detail:
|
Created Date: 1996-10-03 Completed Date: 1996-10-03 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0401175 Medline TA: Jpn Heart J Country: JAPAN |
Other Details:
|
Languages: eng Pagination: 327-32 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Juntendo University, School of Medicine, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary* Anticholesteremic Agents / therapeutic use* Coronary Artery Disease / prevention & control, therapy* Female Humans Male Middle Aged Pravastatin / therapeutic use Probucol / therapeutic use* Prospective Studies Recurrence |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 23288-49-5/Probucol; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Significant characteristics of variant angina patients with associated syncope.
Next Document: Assessment of left atrial pressure and volume changes during atrial systole with transesophageal pul...